scholarly journals Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0244046
Author(s):  
Keyword(s):  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Virus Vector ◽  
Hiv 1

scholarly journals Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
Author(s):  
Sunil K. Khattar ◽  
Sweety Samal ◽  
Celia C. LaBranche ◽  
David C. Montefiori ◽  
Peter L. Collins ◽  
...  
Keyword(s):  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Virus Vector ◽  
Hiv 1

scholarly journals Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e78521 ◽  
Author(s):  
Sunil K. Khattar ◽  
Sweety Samal ◽  
Celia C. LaBranche ◽  
David C. Montefiori ◽  
Peter L. Collins ◽  
...  
Keyword(s):  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Virus Vector ◽  
Hiv 1

scholarly journals Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges

mBio ◽  
2015 ◽  
Vol 6 (4) ◽  
Author(s):  
Sunil K. Khattar ◽  
Vinoth Manoharan ◽  
Bikash Bhattarai ◽  
Celia C. LaBranche ◽  
David C. Montefiori ◽  
...  
Keyword(s):  
Immune Responses ◽  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Effective Vaccine ◽  
Gag Proteins ◽  
Humoral Immune ◽  
Vaccinia Viruses ◽  
Mucosal Immune Responses ◽  
Hiv 1

ABSTRACT Newcastle disease virus (NDV) avirulent strain LaSota was used to coexpress gp160 Env and p55 Gag from a single vector to enhance both Env-specific and Gag-specific immune responses. The optimal transcription position for both Env and Gag genes in the NDV genome was determined by generating recombinant NDV (rNDV)-Env-Gag (gp160 located between the P and M genes and Gag between the HN and L genes), rNDV-Gag-Env (Gag located between the P and M genes and gp160 between the HN and L genes), rNDV-Env/Gag (gp160 followed by Gag located between the P and M genes), and rNDV-Gag/Env (Gag followed by gp160 located between the P and M genes). All the recombinant viruses replicated at levels similar to those seen with parental NDV in embryonated chicken eggs and in chicken fibroblast cells. Both gp160 and Gag proteins were expressed at high levels in cell culture, with gp160 found to be incorporated into the envelope of NDV. The Gag and Env proteins expressed by all the recombinants except rNDV-Env-Gag self-assembled into human immunodeficiency virus type 1 (HIV-1) virus-like particles (VLPs). Immunization of guinea pigs by the intranasal route with these rNDVs produced long-lasting Env- and Gag-specific humoral immune responses. The Env-specific humoral and mucosal immune responses and Gag-specific humoral immune responses were higher in rNDV-Gag/Env and rNDV-Env/Gag than in the other recombinants. rNDV-Gag/Env and rNDV-Env/Gag were also more efficient in inducing cellular as well as protective immune responses to challenge with vaccinia viruses expressing HIV-1 Env and Gag in mice. These results suggest that vaccination with a single rNDV coexpressing Env and Gag represents a promising strategy to enhance immunogenicity and protective efficacy against HIV. IMPORTANCE A safe and effective vaccine that can induce both systemic and mucosal immune responses is needed to control HIV-1. In this study, we showed that coexpression of Env and Gag proteins of HIV-1 performed using a single Newcastle disease virus (NDV) vector led to the formation of HIV-1 virus-like particles (VLPs). Immunization of guinea pigs with recombinant NDVs (rNDVs) elicited potent long-lasting systemic and mucosal immune responses to HIV. Additionally, the rNDVs were efficient in inducing cellular immune responses to HIV and protective immunity to challenge with vaccinia viruses expressing HIV Env and Gag in mice. These results suggest that the use of a single NDV expressing Env and Gag proteins simultaneously is a novel strategy to develop a safe and effective vaccine against HIV.

scholarly journals Development of a Newcastle disease virus vector expressing a foreign gene through an internal ribosomal entry site provides direct proof for a sequential transcription mechanism

2015 ◽  
Vol 96 (8) ◽  
pp. 2028-2035 ◽  
Author(s):  
Zhenyu Zhang ◽  
Wei Zhao ◽  
Deshan Li ◽  
Jinlong Yang ◽  
Laszlo Zsak ◽  
...  
Keyword(s):  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Internal Ribosomal Entry Site ◽  
Direct Proof ◽  
Virus Vector ◽  
Foreign Gene ◽  
Entry Site ◽  
Ribosomal Entry

scholarly journals Newcastle disease virus f glycoprotein expressed from a recombinant vaccinia virus vector protects chickens against live‐virus challenge

1988 ◽  
Vol 17 (4) ◽  
pp. 821-827 ◽  
Author(s):  
G. Meulemans ◽  
C. Letellier ◽  
M. Gonze ◽  
M.C. Carlier ◽  
A. Burny
Keyword(s):  
Newcastle Disease Virus ◽  
Vaccinia Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Recombinant Vaccinia Virus ◽  
Virus Vector ◽  
Live Virus ◽  
Recombinant Vaccinia ◽  
Virus Challenge ◽  
Vaccinia Virus Vector

scholarly journals Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus

2015 ◽  
Vol 11 (2) ◽  
pp. 504-515 ◽  
Author(s):  
Sunil K Khattar ◽  
Senthilkumar Palaniyandi ◽  
Sweety Samal ◽  
Celia C LaBranche ◽  
David C Montefiori ◽  
...  
Keyword(s):  
Immune Responses ◽  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Cellular Immune Responses ◽  
Cellular Immune ◽  
Hiv 1

scholarly journals Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs

mBio ◽  
2021 ◽  
Author(s):  
Jesús Horacio Lara-Puente ◽  
Juan Manuel Carreño ◽  
Weina Sun ◽  
Alejandro Suárez-Martínez ◽  
Luis Ramírez-Martínez ◽  
...  
Keyword(s):  
Newcastle Disease Virus ◽  
Disease Virus ◽  
Newcastle Disease ◽  
Vaccine Candidate ◽  
Low Cost ◽  
Production Capacity ◽  
Virus Vector ◽  
Preclinical Testing ◽  
Global Demand ◽  
Current Production

Several highly efficacious vaccines for SARS-CoV-2 have been developed and are used in the population. However, the current production capacity cannot meet the global demand. Therefore, additional vaccines—especially ones that can be produced locally and at low cost—are urgently needed. This work describes preclinical testing of a SARS-CoV-2 vaccine candidate which meets these criteria.

Sign in / Sign up

Export Citation Format

Share Document